Company / Cash & Equivalents
DNA X, Inc. Cash & Equivalents History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$5.3M
FY2024
5-year range
$5.3M / $22.1M
FY2020-FY2024
Trend
-43.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 3 consecutive years, from $22M in FY2021 to $5M in FY2024.
Based on SEC 10-K filings.
$5M in FY2024 with a 5-year CAGR of -13.9%.
Declined from $13M to $5M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -37.7%
- 5-Year CAGR
- -13.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- DNA X, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of -13.9%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 43.1% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $5.3M | -43.1% |
| FY2023 | $9.4M | -28.9% |
| FY2022 | $13.2M | -40.3% |
| FY2021 | $22.1M | +0.0% |
| FY2020 | $22.1M | +96.0% |
| FY2019 | $11.3M | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026